They get through phase ll there will be a partnership and you already know that...don't have the time or inclination to list the myriad examples of that circumstance occurring in the biotech sector
What you said, and what I was disagreeing with, is that there would be a need for more dilutive financing to pay for tests. The fact is, Phase 2 trials most often lead license agreements on very strong terms. A license with benchmarks would be sufficient income to complete several other versions of viricides. After a successful Phase 2 trial there would be no need for any more dilution through share selling.
THAT isn't what i said…i said they have NOT done toxicity tests…they are NOT in FDA trials or even scheduled for it….therefor they are NOWHERE near having a marketable drug nor will they in the near future……imo shareholders better prepare for more dilution….they have money for the toxicity tests and through phase II?….last time i checked it takes Phase III as well.